Genova Diagnostics: The Specialty Lab That Paid Physicians to Order Stool Tests Medicare Said Were Rarely Medically Necessary

Genova Diagnostics Inc., a specialty clinical laboratory focused on gastrointestinal and nutritional testing, agreed to pay $43.5 million to resolve False Claims Act and Anti-Kickback Statute allegations that it paid remuneration to physician practices to induce the ordering of its gastrointestinal stool testing panels, then submitted claims to Medicare and Medicaid for those tests without adequate documentation of medical necessity — generating federal health program payments for specialty testing that regulators found was ordered at least in part because of Genova's financial relationships with the ordering practices rather than because of genuine clinical indications for the individual patients tested.DOCUMENTED

The case reflects a recurring enforcement pattern in the specialty laboratory testing sector, where laboratories with higher-reimbursement testing panels have strong financial incentives to build physician ordering relationships through arrangements that provide value to the ordering practice. When those arrangements cross the line from legitimate marketing and education into remuneration that induces referrals, they violate the Anti-Kickback Statute regardless of whether the individual tests ordered were clinically appropriate. The statute's concern is the contamination of clinical judgment by financial incentive — a test ordered because the laboratory pays the physician more than a test ordered purely on clinical grounds, even if the test itself was one the physician would have ordered anyway.REVIEWED

The Physician Relationship Arrangements

Genova's sales model relied on building direct relationships with physician practices that ordered gastrointestinal and nutritional testing for their patients. The arrangements identified in the complaint included providing test collection kits to practices at no charge or at below-cost rates, supplying specimen collection and handling materials as practice amenities beyond what was necessary for simple specimen collection, and in some arrangements providing practice support services that had value to the practice independent of any legitimate per-patient testing purpose.DOCUMENTED

The Anti-Kickback Statute's safe harbors for laboratory relationships with physician practices are carefully bounded — laboratories may provide collection supplies necessary for the physical act of collecting the specimen, but providing supplies or services that go beyond that limited purpose and that have general value to the practice as a business crosses the safe harbor's boundary. The safe harbor's logic is that providing genuine value to a practice — value beyond what is necessary for the specimen collection — creates the financial inducement that the statute prohibits, regardless of how the arrangement is characterized in the laboratory's contracting documents.REVIEWED

The Medical Necessity Question

Genova's specialty stool testing panels — which assessed gastrointestinal microbiome composition, digestive enzyme function, intestinal permeability, and related markers — are not routine clinical tests covered by standard laboratory fee schedules. They are specialty panels with higher reimbursement rates that Medicare covers only when there is documented clinical justification for the specific tests ordered in the context of the individual patient's presentation. Regulators' clinical review of a sample of claims found that a significant portion of the tested patients lacked the clinical documentation that would support a finding of medical necessity for the specific panel elements billed.DOCUMENTED

The intersection of the kickback findings and the medical necessity findings is central to the False Claims Act theory: tests that were ordered because of Genova's physician relationship arrangements, rather than or in addition to genuine clinical indications, were false claims both because they were induced by an unlawful kickback and because the absence of adequate clinical justification meant the claims lacked the medical necessity required for Medicare and Medicaid coverage.DOCUMENTED

A clinical review of sampled claims found that ordering notes for many tested patients did not document the specific symptoms, diagnoses, or prior treatment failures that Medicare's coverage criteria required to justify the specialty gastrointestinal testing panels Genova billed.

Whistleblower Origins

The investigation originated with a qui tam complaint filed under the False Claims Act by a former Genova employee who had direct knowledge of the physician arrangement practices and billing patterns from their time working inside the company. The whistleblower's account described the arrangements from the inside — the rationale internal to the company for building and maintaining physician relationships through financial arrangements, the understanding among sales staff that those arrangements generated ordering volume, and the gap between the clinical documentation standard and what the company was actually receiving as support for the claims it submitted.DOCUMENTED

The relator in this case will receive a statutory percentage of the $43.5 million recovery as a qui tam share. False Claims Act qui tam provisions are designed precisely to incentivize insiders with this type of knowledge to come forward, because the arrangements that generate specialty laboratory fraud are often not visible from the outside — they exist in the internal relationship between the laboratory's sales function and the ordering practices, and government investigators often cannot identify them without the testimony and documentation that a well-positioned insider can provide.REVIEWED

Corporate Integrity Agreement

As part of the settlement, Genova entered a five-year Corporate Integrity Agreement requiring independent review of its physician arrangement compliance on an annual basis, enhanced medical necessity documentation standards for all claims involving specialty testing panels, and mandatory training for all personnel involved in sales, marketing, and billing on Anti-Kickback Statute compliance. The agreement also requires Genova to implement a system for tracking all items of value provided to physician practices and to report annually on those arrangements to confirm their compliance with applicable safe harbors.DOCUMENTED

Physicians who receive items of value from clinical laboratories — including collection supplies, patient materials, practice support services, or any other items beyond basic specimen collection requirements — should evaluate those arrangements against the Anti-Kickback Statute's laboratory safe harbor criteria. Receiving value from a laboratory that exceeds what the safe harbor permits creates risk not only for the laboratory but potentially for the ordering physician, depending on the physician's knowledge of the arrangement's nature and the extent to which it influenced their ordering decisions. Physicians and laboratory employees with knowledge of similar arrangements are encouraged to contact the HHS OIG hotline or Watchdog Journal at /tips.

Have documents relevant to this story? Reach us through our tips channel.